Alivus Life Sciences Limited (BOM: 543322)
India flag India · Delayed Price · Currency is INR
1,012.55
0.00 (0.00%)
At close: Dec 20, 2024

Alivus Life Sciences Company Description

Glenmark Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India.

The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin.

It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies.

The company’s APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives.

It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India.

Glenmark Life Sciences Limited is a subsidiary of Nirma Limited.

Alivus Life Sciences Limited
Country India
Founded 2011
Industry Medicinal Chemicals and Botanical Products
Employees 2,014
CEO Yasir Rawjee

Contact Details

Address:
OIA House
Mumbai, Maharashtra 400099
India
Phone 91 22 6829 7979
Website glenmarklifesciences.com

Stock Details

Ticker Symbol 543322
Exchange Bombay Stock Exchange
Fiscal Year April - March
Reporting Currency INR
SIC Code 2833

Key Executives

Name Position
Yasir Rawjee Chief Executive Officer
Tushar Mistry Chief Financial Officer